Medical Hypotheses
Volume 44, Issue 1 , Pages 39-46 , January 1995

Meditation, melatonin and breast/prostate cancer: Hypothesis and preliminary data

Received 11 May 1994 ,Accepted 24 August 1994.

References 

  1. Spiegel D, Bloom J, Kraemer H, Gotheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2:888–891
  2. Fawzy FI, Fawzy NW, Hyun CS, et al.  Malignant melanoma: effects of an early structured psychiatric intervention, coping and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993;50:681–689
  3. Nir I. Opening remarks. In: Proceedings of the International Symposium ‘The Pineal Gland’. Jerusalem, November 14–17, 1977. 3rd edn. J Neural Transmission. 1978;p. 1–2 Suppl 13
  4. Kabat-Zinn J. Full Catastrophe Living. New York: Delacorte; 1990;
  5. Kabat-Zinn J. An out-patient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. Gen Hosp Psychiatry. 1982;4:33–47
  6. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain. J Behav Med. 1985;8:163–190
  7. Kabat-Zinn J, Lipworth L, Burney R, Sellers W. Four year follow-up of a meditation-based program for the self-regulation of chronic pain: treatment outcomes and compliance. Clin J Pain. 1986;2:159–173
  8. Kabat-Zinn J, Massion AO, Kristeller J, et al.  Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry. 1992;149:936–943
  9. Bernhard JD, Kristeller J, Kabat-Zinn J. Effectiveness of relaxation and visualization techniques as an adjunct to phototherapy and photochemotherapy of psoriasis. J Am Acad Derm. 1988;19:572–573
  10. Spiegel D, Spira J. In: 3rd edn. Supportive-Expressive Group Therapy: A Treatment Manual of Psychosocial Intervention for Women with Recurrent Breast Cancer. Stanford, CA: Psychosocial Treatment Laboratory, Stanford University School of Medicine; 1991;
  11. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Reviews. 1991;12:151–180
  12. McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Melatonin rhythm in human plasma and saliva. J Pineal Res. 1987;4:177–183
  13. Guerrero J, Reiter R. A brief survey of pineal gland-immune system interrelationships. Endocr Res. 1992;18:91–113
  14. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res. 1993;14:151–168
  15. Menendez-Pelaez A, Reiter RJ. Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res. 1993;15:59–69
  16. Lynch H, Deng M. Pineal Responses to Stress. J Neural Transm. 1986;21:461–473 (Suppl)
  17. Maestroni GJM, Conti A. Anti-stress role of the melatoninimmuno-opioid network: evidence for a physiological mechanism involving T cell-derived, immuno-reactive B-endorphin and metenkephalin binding to thymic opioid receptors. Intl J Neurosci. 1991;61:289–298
  18. Maestroni GJM. The immunoneuroendocrine role of melatonin. J Pineal Res. 1993;14:1–10
  19. Khan R, Daya S, Potgieter B. Evidence for a modulation of the stress response by the pineal gland. Experientia. 1990;46:860–862
  20. Pierpaoli W, Maestroni J. Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects. Immunol Lett. 1987;16:355–362
  21. Maestroni GJM, Conti A. Melatonin in relation to the immune system. In:  Yu H-S,  Reiter R editor. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton: CRC Press; 1993;p. 289–309
  22. Fuchs E, Schumacher M. Psychosocial stress affects pineal function in the tree shrew (Tupaia belangeri). Physiol Behav. 1990;47:713–717
  23. Lopez-Gonzalez MA, Calvo JR, Osuna C, Guerrero JM. Interaction of melatonin with human lymphocytes: Evidence for binding sites coupled to potentiation of cyclic AMP stimulated by vasoactive intestinal peptide and activation of cyclic GMP. J Pineal Res. 1992;12:97–104
  24. Lopez-Gonzalez MA, Calvo JR, Osuna C, Rubio A, Guerrero JM. Synergistic action of melatonin and vasoactive intestinal peptide in stimulating cyclic AMP production in human lymphocytes. J Pineal Res. 1992;12:174–180
  25. Lopez-Gonzalez MA, Calvo JR, Osuna C, Rubio A, Guerrero JM. Melatonin potentiates cyclic AMP production stimulated by vasoactive intestinal peptide in human lymphocytes. Neurosci Lett. 1992;136:150–152
  26. Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol. 1993;246:89–96
  27. Blask DE. Melatonin in oncology. In:  Yu H-S,  Reiter R editor. Melatonin: biosynthesis, physiological effects, and clinical applications. Boca Raton: CRC Press; 1993;p. 447–475
  28. Tan D-X, Poeggeler B, Reiter RJ, et al.  The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 1993;70:65–71
  29. Hardeland R, Reiter RJ, Poeggeler B, Tan D-X. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev. 1993;17:347–357
  30. Reiter RJ. Antioxidant capacity of melatonin: a novel action not requiring a receptor. Neuroendocrinol Lett. 1993;15:103–116
  31. Bartsch H, Bartsch C, Simon WE, Flehmig B, Ebels I, Lippert TH. Antitumor activity of the pineal gland: effect of unidentified substances versus the effect of melatonin. Oncology. 1992;49:27–30
  32. Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett. 1992;64:249–256
  33. Danforth DN, Tamarkin L, Lippman ME. Melatonin increased oestrogen receptor binding activity of human breast cancer cells. Nature. 1983;305:323–325
  34. Cos S, Blask D, Lemus-Wilson A, Hill A. Effects of melatonin on the cell cycle kinetics and ‘estrogen-rescue’ of MCF7 human breast cancer cells in culture. J Pineal Res. 1991;10:36–42
  35. Wilson S, Blask D, Lemus-Wilson A. Melatonin augments the sensitivity of MCF-7 human breast cancer cells to tamoxifen in vitro. J Clin Endocrinol Metab. 1992;75:669–670
  36. Elias M. The mysteries of melatonin. Harvard Health Lett. 1993 June;6–8
  37. Miller MW. Drug companies and health-food stores fight to peddle melatonin to insomniacs. The Wall Street Journal. 1994 August 31;B1–B2 Sect B
  38. Lissoni P, Crispino S, Barni S, et al.  Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology. 1990;47:275–277
  39. Lissoni P, Barni S, Taccim G, et al.  A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology. 1993;50:399–402
  40. Lissoni P, Barcini G, Tacm S. Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients. Tumori. 1988;74:339–345
  41. Lissoni P, Tisi E, Barni S, et al.  Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced nonsmall cell lung cancer. Br J Cancer. 1992;66:155–158
  42. Lissoni P, Barni S, Taccini G, et al.  Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract. Br J Cancer. 1993;67:1404–1407
  43. Lissom P, Barni S, Tancini G, et al.  A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer. 1994;69:196–199
  44. Lissoni P, Bari S, Ardizzoia A, Tancini G, Conti A, Maestroni G. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer. 1994;73:699–701
  45. Moon TD. Prostate cancer. J Am Geriatr Soc. 1992;40:622–627
  46. Bartsch C, Bartsch H. Melatonin in human cancer patients. In:  Gupta D,  Attanasio A,  Reiter R editor. The Pineal Gland and Cancer. London: Brain Research Promotion; 1988;p. 361–376
  47. Bartsch C, Bartsch H, Fluchter S-H, Attanasio A, Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J Pineal Res. 1985;2:121–132
  48. Philo R, Berkowitz AS. Inhibition of Dunning tumor growth by melatonin. J Urol. 1988;139:1099–1102
  49. Buzzell GR. Studies on the effects of the pineal hormone melatonin on an androgen-insensitive rat prostatic adenocarcinoma, the Dunning R 3327 HIF tumor. J Neural Transm. 1988;72:131–140
  50. Bartsch C. Melatonin and 6-sulphatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients. Clin Chim Acta. 1992;209:153–167
  51. Bartsch C, Bartsch H. Melatonin secretion in oncological patients: current results and methodological considerations. In:  Maestroni GJM,  Maestroni CA,  Reiter RJ editor. Advances in Pineal Research: 7. New York: John Libbey & Co; 1994;p. 283–301
  52. Anderson RA, Lincoln GA, Wu FCW. Melatonin potentiates testosterone-induced suppression of luteinizing hormone secretion in normal men. Num Reprod. 1993;8:1819–1822
  53. Gittes RF. Carcinoma of the prostate. New Engl J Med. 1991;324:236–245
  54. Relkin R. The Pineal. In: Montreal: Eden Press; 1976;p. 76–79
  55. Bujatti M, Riederer P. Serotonin, noradrenaline, dopamine metabolites in transcendental meditation-technique. J Neural Transm. 1976;39:257–267
  56. Romijn HJ. Minireview: the pineal, a tranquilizing organ?. Life Sci. 1978;23:2257–2274
  57. Callaway JC. A proposed mechanism for the visions of dream sleep. Med Hypotheses. 1988;26:119–124
  58. Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp Ther. 1983;227:587–591
  59. Lakin ML, Miller CH, Stott ML, Winters WD. Involvement of the pineal gland and melatonin in murine analgesia. Life Sci. 1981;29:2543–2551
  60. Woolfolk RL, Carr-Kaffashan L, McNulty TF, Lehrer PM. Meditation training as a treatment for insomnia. Behav Ther. 1976;7:359–365
  61. Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature and performance. In: 3rd edn. Proc Natl Acad Sci USA. 91:1994;p. 1824–1828
  62. Ferini-Strambi L, Zucconi M, Biella G, et al.  Effect of melatonin on sleep microstructure: preliminary results in healthy subjects. Sleep. 1993;16:744–747
  63. Stankov B, Fraschim F, Reiter RJ. The melatonin receptor: distribution, biochemistry, and pharmacology. In:  Yu H-S,  Reiter R editor. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton: CRC Press; 1993;p. 156–186
  64. Demisch L. Clinical pharmacology of melatonin regulation. In:  Yu H-S,  Reiter R editor. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton: CRC Press; 1993;p. 513–540
  65. Delmonte MM. Physiological concomitants of meditation practice. Int J Psychosom. 1984;31:23–36
  66. Delmonte MM. Physiological responses during meditation and rest. Biofeedback and Self Regul. 1984;9:181–200
  67. Chuang JI, Chen SS, Lin MT. Melatonin decreases brain serotonin release, arterial pressure and heart rate in rats. Pharmacology. 1993;47:91–97
  68. Kabat-Zinn J, Skillings A, Santorelli SF. Sense of Coherence and Stress Hardiness as predictors and measures of outcome of a stress reduction program. In: Poster presented at the annual meeting of the Society of Behavioral Medicine. San Francisco. 1989; (March 31)
  69. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry. 1990;51(1 Suppl):3–10
  70. Bojkowski CJ, Arendt J. Annual changes in 6-sulphatoxymelatonin excretion in man. Acta Endocrinol (Copenh). 1988;117:470–476
  71. Bojkowski CJ, Arendt J, Shih MC, Markey SP. Melatonin secretion in humans assessed by measuring its metabolite, 6-sulphatoxymelatonin. Clin Chem. 1987;33:1343–1348
  72. In: 3rd edn. SAS Users Guide. Cary, NC: SAS Institute; 1993;

☆ Supported by the Behavioral Neurosciences Laboratories, Department of Psychiatry, University of Massachusetts Medical Center and Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School.

PII: 0306-9877(95)90299-6

Medical Hypotheses
Volume 44, Issue 1 , Pages 39-46 , January 1995

Article Tools